ZEOX · XBRL financial data
Zeo ScientifiX financial statements, every fiscal year
The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ZEOX's year ends in late June)
| In millions of dollars | Oct 31, 2021 | Oct 31, 2022 | †Oct 31, 2023 | Oct 31, 2024 | Oct 31, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Revenue | 6 | 6 | 5 | 5 | 5 | — |
| Cost of revenue | 1 | 1 | 1 | 1 | 1 | — |
| Cost of goods and services sold | — | — | — | 1 | 1 | — |
| Gross profit | 5 | 6 | 4 | 4 | 4 | — |
| Research and development | 1 | 1 | 1 | 0 | 0 | — |
| General and administrative | 18 | 15 | 11 | 9 | 10 | — |
| Operating income (loss) | (13) | (9) | (7) | (5) | (5) | — |
| Interest expense | 0 | 0 | 0 | 0 | 0 | — |
| Other income (expense) | 0 | 0 | (0) | 1 | 0 | — |
| Income tax expense (benefit) | 0 | — | — | — | — | — |
| Net income (loss) | (13) | (9) | (7) | (5) | (6) | — |
| Earnings per share, basic USD per share | — | (1.56) | (0.99) | (0.74) | (0.86) | — |
| Earnings per share, diluted USD per share | — | (1.56) | (0.99) | (0.74) | (0.86) | — |
| Weighted average shares, basic millions of shares | — | 6 | 7 | 6 | 6 | — |
| Weighted average shares, diluted millions of shares | — | 6 | 7 | 6 | 6 | — |
- † Share count changed about 1/239 in the period ending 2023-10-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (ZEOX's year ends in late June)
| In millions of dollars | Oct 31, 2021 | Oct 31, 2022 | †Oct 31, 2023 | Oct 31, 2024 | Oct 31, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 4 | 2 | 1 | 0 | 2 |
| Marketable securities, non-current | — | 0 | — | — | — | — |
| Accounts receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 1 |
| Total current assets | 1 | 4 | 2 | 1 | 1 | 3 |
| Property and equipment, net | 1 | 2 | 1 | 0 | 1 | 1 |
| Total assets | 2 | 6 | 3 | 2 | 2 | 4 |
| Accrued liabilities | 2 | — | — | — | — | — |
| Current portion of long-term debt | 0 | 1 | 1 | 1 | 0 | 0 |
| Total current liabilities | 4 | 4 | 4 | 3 | 3 | 3 |
| Lease liability, non-current | 0 | 0 | — | — | — | — |
| Total liabilities | 5 | 4 | 4 | 3 | 3 | 3 |
| Accumulated deficit | (42) | (51) | (58) | (62) | (68) | (73) |
| Total stockholders' equity | (3) | 2 | (1) | (2) | (1) | 1 |
| Total liabilities and equity | 2 | 6 | 3 | 2 | 2 | 4 |
| Common shares outstanding (cover page) millions of shares | 1,149 | 1,464 | 6 | 6 | 8 | 8 |
- † Share count changed about 1/239 in the period ending 2023-10-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (ZEOX's year ends in late June)
| In millions of dollars | Oct 31, 2021 | Oct 31, 2022 | †Oct 31, 2023 | Oct 31, 2024 | Oct 31, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (13) | (9) | (7) | (5) | (6) | — |
| Stock-based compensation | 9 | 4 | 3 | 4 | 5 | — |
| Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | — |
| Net cash from operating activities | (3) | (3) | (2) | (1) | (1) | — |
| Purchases of property and equipment | 0 | 1 | 0 | — | 0 | — |
| Net cash from investing activities | (0) | (1) | 1 | (0) | (0) | — |
| Proceeds from issuing common stock | 3 | 7 | 0 | 1 | 0 | — |
| Net cash from financing activities | 3 | 8 | (0) | 0 | 0 | — |
- † Share count changed about 1/239 in the period ending 2023-10-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Zeo ScientifiX | 2.3 | not reported | not reported | 7.8M | — | 10-KTJun 30, 2026 |
| Sunshine Biopharma | 14 | 9.3 | (0.9)* | 3.9M | 15.0 quarters | 10-QJun 30, 2026 |
| Neuphoria Therapeutics | 20 | year only | 1.2* | 5.4M | — | 10-KJun 30, 2026 |
| CV Sciences | 0.3 | 3 | 0* | 225.8M | — | 10-QJun 30, 2026 |
| Minerva Neurosciences | 25 | not reported | (13)* | 47.7M | 5.6 quarters | 10-QJun 30, 2026 |
| Bolt Biotherapeutics | 13 | 0 | (6.5)* | 1.9M | 2.7 quarters | 10-QJun 30, 2026 |
| Intensity Therapeutics | 9.5 | not reported | (2.3)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| Genprex | 15 | not reported | (5.1)* | 819,709 | 2.9 quarters | 10-QJun 30, 2026 |
| VivoSim Labs | 1.7 | 0 | (3.2) | 14.9M | 0.5 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.